Bradley Connor
Gastroenterology · New York, NYNPI 1366529620
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Valneva USA, Inc. accounts for 67.9% of it on its own, with 18 other manufacturers making up the rest. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1700.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valneva USA, Inc.$135K
- Biomerieux Inc$32K
- Redhill Biopharma Inc.$10K
- Biofire Diagnostics, LLC$9K
- Emergent Biosolutions Inc.$5K
- Mayne Pharma Commercial LLC$5K
- plus $3K from 13 others
Across 45 payments — averaging $18,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$518K
- Biofire Diagnostics, LLC$301K
What the payments were for
- Consulting fees$102,18451%
- Speaking & faculty fees$66,45033%
- Grants$10,0005%
- Travel & lodging$12,7736%
- Food & beverage$7,5134%
- Education$120%
- Other$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valneva USA, Inc. | 59 | $135,179 |
| Biomerieux Inc | 13 | $31,674 |
| Redhill Biopharma Inc. | 8 | $9,665 |
| Biofire Diagnostics, LLC | 9 | $9,449 |
| Emergent Biosolutions Inc. | 2 | $5,200 |
| Mayne Pharma Commercial LLC | 2 | $5,125 |
| GSK | 1 | $1,800 |
| Phathom Pharmaceuticals, Inc. | 3 | $278 |
| QOL Medical, LLC | 1 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $116 |
| Boston Scientific | 4 | $79 |
| Lupin Inc. | 1 | $64 |
| Pfizer | 2 | $56 |
| Ironwood Pharmaceuticals, Inc | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Merck | 1 | $17 |
| Fujifilm Healthcare Americas Corporation | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IXIARO$69,874
- FILMARRAY GASTROINTESTINAL (GI) PANEL$9,789
- IXCHIQ$9,000
- BIOFIRE FILMARRAY Tropical Fever Panel$8,851
- FILMARRAY PNEUMONIA PANEL (PNEUMO)$7,539
- TOLSURA$5,125
- AEMCOLO$5,000
- Talicia$4,065
- BioFire FilmArray$2,100
- BIOFIRE RESPIRATORY PANEL 2.1$1,500
- VOQUEZNA$250
- Sucraid$147
How this compares
$198,946 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $10,623 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 60 | $2,607 |
| Azithromycin | 84 | $253 |
| Zolpidem Tartrate | 11 | $145 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.